Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1981 Dec;44(6):856–862. doi: 10.1038/bjc.1981.284

Lower relapse rates after neighbourhood injection of Corynebacterium parvum in operable cervix carcinoma.

M H Mignot, J W Lens, H A Drexhage, B M von Blomberg, V D Flier, J Oort, J G Stolk
PMCID: PMC2010856  PMID: 7326194

Abstract

The effect of adjuvant immunotherapy with a single neighbourhood injection of 2 mg C. parvum (CP) was investigated in a randomized study involving 43 patients with carcinoma of the cervix uteri, all of whom were treated by radical surgery. All patients had carcinoma confined to the cervix, the upper part of the vagina or the parametrial region. When the malignancy had spread to the parametrial region, additional postoperative radiotherapy was given. 22 patients received immunotherapy 10 days before surgery, whereas the remaining 21 control patients received no immune stimulation. Only minor side effects of CP were encountered. Follow-up shows a relapse rate of 5% in the CP treated group and of 29% in the controls (P less than 0.05). A further 15 patients with more advanced malignancies were added to our studies. In these, CP stimulation had no effect on relapse rates, but the relapse-free intervals were longer after immune stimulation: control 3.5 months (mean) +/- 1.5 (s.d.), CP 13.0 months +/- 7.0 (P less than 0.05). The number of peripheral T cells and the ability to become sensitized to DNCB were increased after CP stimulation. A decrease was found in the number of blood monocytes and the number of monocytes capable of transforming into active macrophages, indicating a possible sequestration of these cells in the tissues.

Full text

PDF
856

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boetcher D. A., Leonard E. J. Abnormal monocyte chemotactic response in cancer patients. J Natl Cancer Inst. 1974 Apr;52(4):1091–1099. doi: 10.1093/jnci/52.4.1091. [DOI] [PubMed] [Google Scholar]
  2. Currie G. A., Hedley D. W. Monocytes and macrophages in malignant melanoma. I. Peripheral blood macrophage precursors. Br J Cancer. 1977 Jul;36(1):1–6. doi: 10.1038/bjc.1977.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dykes P. W., Trejdosiewicz L. K. Intra-tumour C. parvum therapy in gastric carcinoma; a pilot study. Dev Biol Stand. 1977 Apr 13;38:547–552. [PubMed] [Google Scholar]
  4. Elhilali M. M., Brosman S. A., Vescera C., Paul J. G., Fahey J. L. The effects of treatment on delayed cutaneous hypersensitivity responses (DNCB, croton oil, and recall antigen) in patients with genitourinary cancer. Cancer. 1978 May;41(5):1765–1770. doi: 10.1002/1097-0142(197805)41:5<1765::aid-cncr2820410518>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  5. Engvall E., Perlmann P. Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. J Immunol. 1972 Jul;109(1):129–135. [PubMed] [Google Scholar]
  6. Griffiths J. D., McKinna J. A., Rowbotham H. D., Tsolakidis P., Salsbury A. J. Carcinoma of the colon and rectum: circulating malignant cells and five-year survival. Cancer. 1973 Jan;31(1):226–236. doi: 10.1002/1097-0142(197301)31:1<226::aid-cncr2820310130>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  7. Hausman M. S., Brosman S., Snyderman R., Mickey M. R., Fahey J. Defective monocyte function in patients with genitourinary carcinoma. J Natl Cancer Inst. 1975 Nov;55(5):1047–1054. doi: 10.1093/jnci/55.5.1047. [DOI] [PubMed] [Google Scholar]
  8. Jansen H. M., The T. H., Orie N. G. Adjuvant immunotherapy with BCG in squamous cell bronchial carcinoma. Thorax. 1980 Oct;35(10):781–787. doi: 10.1136/thx.35.10.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kirchner H., Peter H. H., Hirt H. M., Zawatzky R., Dalügge H., Bradstreet P. Studies of the producer cell of interferon in human lymphocyte cultures. Immunobiology. 1979 Aug;156(1-2):65–75. [PubMed] [Google Scholar]
  10. Lacour J., Lacour F., Spira A., Michelson M., Petit J. Y., Delage G., Sarrazin D., Contesso G., Viguier J. Adjuvant treatment with polyadenylic-polyuridylic acid (Polya.Polyu) in operable breast cancer. Lancet. 1980 Jul 26;2(8187):161–164. doi: 10.1016/s0140-6736(80)90057-4. [DOI] [PubMed] [Google Scholar]
  11. MOLLER G. Studies on the mechanism of immunological enhancement of tumor homografts. III. Interaction between humoral isoantibodies and immune lymphoid cells. J Natl Cancer Inst. 1963 Jun;30:1205–1226. [PubMed] [Google Scholar]
  12. Millar J. W., Hunter A. M., Horne N. W. Treatment of malignant effusions. Lancet. 1981 Mar 28;1(8222):726–727. doi: 10.1016/s0140-6736(81)92006-7. [DOI] [PubMed] [Google Scholar]
  13. Minton J. P., Rossio J. L., Dixon B., Dodd M. C. The effect of Corynebacterium parvum on the humoral and cellular immune systems in patients with breast cancer. Clin Exp Immunol. 1976 Jun;24(3):441–447. [PMC free article] [PubMed] [Google Scholar]
  14. Mullink H., Von Blomberg M., Wilders M. M., Drexhage H. A., Alons C. L. A simple cytochemical method for distinguishing EAC rosettes formed by lymphocytes and monocytes. J Immunol Methods. 1979;29(2):133–137. doi: 10.1016/0022-1759(79)90062-0. [DOI] [PubMed] [Google Scholar]
  15. ROBERTS S., JONASSON O LONG L., McGRATH R., McGREW E. A., COLE W. H. Clinical significance of cancer cells in the circulating blood: two- to five-year survival. Ann Surg. 1961 Sep;154:362–371. doi: 10.1097/00000658-196109000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Scott M. T. Biological effects of the adjuvant Corynebacterium parvum. II. Evidence for macrophage-T-cell interaction. Cell Immunol. 1972 Nov;5(3):469–479. doi: 10.1016/0008-8749(72)90073-1. [DOI] [PubMed] [Google Scholar]
  17. Tarpley J. L., Twomey P. L., Catalona W. J., Chretien P. B. Suppression of cellular immunity by anesthesia and operation. J Surg Res. 1977 Mar;22(3):195–201. doi: 10.1016/0022-4804(77)90134-2. [DOI] [PubMed] [Google Scholar]
  18. Thatcher N., Swindell R., Crowther D. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations. Clin Exp Immunol. 1979 Jan;35(1):36–44. [PMC free article] [PubMed] [Google Scholar]
  19. WOODRUFF M. F. New approaches to the treatment of cancer. J R Coll Surg Edinb. 1961 Jan;6:75–92. [PubMed] [Google Scholar]
  20. Wybran J., Fudenberg H. H. Thymus-derived rosette-forming cells in various human disease states: cancer, lymphoma, bacterial and viral infections, and other diseases. J Clin Invest. 1973 May;52(5):1026–1032. doi: 10.1172/JCI107267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. de Gast G. C., The T. H., Schraffordt Koops H., Huiges H. A., Oldhoff J., Nieweg H. O. Humoral and cell-mediated immune response in patients with malignant melanoma. I. In vitro lymphocyte reactivity to PHA and antigens following immunization. Cancer. 1975 Oct;36(4):1289–1297. doi: 10.1002/1097-0142(197510)36:4<1289::aid-cncr2820360415>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  22. de Graaff J. The Mitra Schauta operation in combination with preoperative irradiation as treatment for carcinoma of the cervix. Gynecol Oncol. 1980 Dec;10(3):267–272. doi: 10.1016/0090-8258(80)90093-1. [DOI] [PubMed] [Google Scholar]
  23. von Blomberg B. M., Glerum J., Croles J. J., Stam J., Drexhage H. A. Harmful effects of i.v. Corynebacterium Parvum given at the same time as cyclophosphamide in patients with squamous-cell carcinoma of the bronchus. Br J Cancer. 1980 Apr;41(4):609–617. doi: 10.1038/bjc.1980.104. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES